Hansoh Pharma Announces Positive Phase II Clinical Results of HS-20137 for Psoriasis Presented as Late-Breaking Oral Presentation at AAD 2025

On March 9, Hansoh Pharmaceutical Group Company Limited announced that the positive results of the Phase II clinical study of HS-20137 Injection (a humanized IgG1 monoclonal antibody targeting IL-23), developed in collaboration with Jiangsu Quanxin Biopharmaceutical Co., Ltd., were presented as a late-breaking oral report at the 2025 American Academy of Dermatology Annual Meeting (2025 AAD Annual Meeting).

HS-20137 Injection is a recombinant humanized IgG1 monoclonal antibody that specifically binds to human IL-23, classified as a Class 1 innovative biologic therapeutic. HS-20137 works by specifically binding to the p19 subunit of human IL-23, blocking the interaction between extracellular IL-23 and the IL-23 receptor on the cell surface, and inhibiting the release of pro-inflammatory cytokines and chemokines mediated by IL-23, thereby achieving therapeutic effects for psoriasis.

To evaluate the efficacy, safety, and pharmacokinetic characteristics of HS-20137 in adult patients with moderate to severe plaque psoriasis, this study adopted a randomized, double-blind, placebo-controlled trial design spanning 52 weeks. A total of 159 subjects were enrolled, with 156 completing the primary endpoint assessment. The study results showed that HS-20137 demonstrated impressive primary endpoint data for treating psoriasis, with rapid effectiveness after the first injection and continuous improvement in subjects' quality of life. Over the 28-week treatment period, HS-20137 exhibited strong efficacy and good safety in patients with moderate to severe plaque psoriasis. After 16 weeks of treatment, up to 76.9% of subjects achieved a 90% improvement in Psoriasis Area and Severity Index (PASI) scores from baseline, and after 24 weeks, this proportion increased to 89.7%.

The phase II study results reported at this year's AAD conference further confirm the efficacy of HS-20137 in treating psoriasis, consistent with the phase I study results published in JAMA Dermatology.